Melanoma Complicating Treatment With Natalizumab for Multiple Sclerosis: A Report From the Southern Network on Adverse Reactions (SONAR)

Cancer Medicine - United Kingdom
doi 10.1002/cam4.1098
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Natalizumab Treatment in Multiple Sclerosis

Clinical Neurology
Neurology
2015English

Natalizumab: A New Treatment for Relapsing Remitting Multiple Sclerosis

Therapeutics and Clinical Risk Management
Chemical HealthPharmacologySafetyMedicineToxicologySafety ResearchPharmaceutics
2007English

Clinical Effects of Natalizumab on Multiple Sclerosis Appear Early in Treatment Course

Journal of Neurology
Neurology
2013English

Natalizumab Therapy for Highly Active Pediatric Multiple Sclerosis

JAMA Neurology
Neurology
2013English

Natalizumab Versus Fingolimod and Dimethyl Fumarate in Multiple Sclerosis Treatment

Annals of Clinical and Translational Neurology
NeuroscienceNeurology
2018English

Predictors for Multiple Sclerosis Relapses After Switching From Natalizumab to Fingolimod

Multiple Sclerosis
Neurology
2014English

Pnd12 - Natalizumab Versus Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Correction To: Switching From Natalizumab to Fingolimod Treatment in Multiple Sclerosis: Real Life Data From the Austrian MS Treatment Registry

Journal of Neurology
Neurology
2019English

Longitudinal Evaluation of Cognitive Functioning in Pediatric Multiple Sclerosis: Report From the US Pediatric Multiple Sclerosis Network

Multiple Sclerosis
Neurology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy